Skip to main content
. 2019 Jan 23;13:405–422. doi: 10.2147/DDDT.S187690

Table 5.

HR estimates of progression-free survival between statins and lung cancer

No. of reports Pooled HR (95% CI) I2 (%) P for heterogeneity
Overall estimation 6 0.93 (0.76–1.13) 39.90 0.14
Subgroup analysis
Study design
 Cohort 3 0.74 (0.47–1.17) 58.50 0.29
 RCT 3 0.99 (0.87–1.13) 0 0.37
Cancer type
 NSCLC 5 0.88 (0.65–1.19) 50.10 0.093
 SCLC 1 0.98 (0.85–1.13)
Combined treatment
 TKIs 3 0.85 (0.49–1.49) 70.90 0.032
 Chemotherapy 2 0.99 (0.86–1.12) 0.00 0.836

Abbreviations: NSCLC, non-small-cell lung cancer; RCT, randomized controlled trial; SCLC, small cell lung cancer; TKIs, tyrosine kinase inhibitors.